Fig. 1

CAFs mediate lung cancer cells proliferation and EGFR TKIs resistance. A, the percentage of CD90 positive cells in the CD45+ cells subpopulation isolated from lung cancer patients’ tumor tissues, which is divided into drug-resistant (D-R) and drug-sensitive (D-S) groups (n = 20). B, CD45+/CD90+ cells sorting using flow cytometry from tumor tissues, and Western blotting of α-SMA in tumor cells (TCs) and CD45+/CD90+ CAFs isolated from NSCLS patients’ tumor tissues. C, the schematic diagram of tumor cells and CAFs co-culture system. D, the relative cells proliferation of A549 cells pre-cultured with PBS, HFL1, and CAFs isolated from patients (fibroblast: tumor cells, 1:5, 48 hours). the relative cells proliferation of Lewis cells was pre-cultured with PBS, HFL1, and CAFs isolated from C57BL/6 (fibroblast: tumor cells, 1:5, 48 hours). E, cytotoxicity of A549 cells pre-cultured with PBS, HFL1, CAFs to Erl (5 μM, 48 hours) and Gef (10 μM, 48 hours). F, cytotoxicity of Lewis cells pre-cultured with PBS, NIH-3 T3, CAFs to Erl (5 μM, 48 hours) and Gef (10 μM, 48 hours). * indicates P < 0.05. ** indicates P < 0.01. n.s. indicates no statistical significance